Nannan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nannan Liu has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Shen Li
Institute of Mental Health, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, China
7 shared publications Xinxu Wang
Laboratory of Biological Psychiatry, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin 300222, China
6 shared publicationsYanzhe Li
Laboratory of Biological Psychiatry, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin 300222, China
6 shared publicationsChenghao Lu
Laboratory of Biological Psychiatry, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin 300222, China
5 shared publications- Jie Li
Laboratory of Biological Psychiatry, Institute of Mental Health, Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, China
5 shared publications Lijun Wang
3 shared publications
Latest Publications
- 14 September 2026
- Published by Elsevier in Brain Research
- Vol. 1892, 150549
Integrated proteomics and network pharmacology reveal autophagy-lysosomal regulation underlying sulforaphane-mediated neuroprotection in Alzheimer’s disease
- 14 September 2026
- Published by Elsevier in Brain Research
- Vol. 1892, 150549
Integrated proteomics and network pharmacology reveal autophagy-lysosomal regulation underlying sulforaphane-mediated neuroprotection in Alzheimer’s disease
- 19 August 2026
- Published by Springer Nature in Molecular Psychiatry
- p. 1-10
Metabolic biomarkers of treatment-resistant schizophrenia and cognitive correlates: insights from a machine learning
Early identification of Treatment-resistant schizophrenia (TRS) remains a challenge. Metabolomics offers a promising strategy for identifying biomarkers and uncovering the metabolic alterations underlying TRS. Machine learning (ML), increasingly applied in omics research, enables the development of predictive models from complex datasets. This study aimed to develop a metabolomics-based ML model for TRS identification and to examine its association with cognitive impairments. 112 TRS patients, 232 non-TRS patients, and 145 sex- and age-matched healthy controls were recruited in this study. Psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS), and cognitive function was evaluated with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the Toronto Alexithymia Scale (TAS-26). Fasting blood samples were collected from all participants and analyzed by UHPLC-HRMS, enabling the quantification and profiling of 699 metabolites. The resulting data were then subjected to orthogonal partial least squares discriminant analysis (OPLS-DA), and a predictive model was constructed using a random forest algorithm, which was validated through 5 × 5 nested cross-validation with inner-loop LASSO feature selection. From 699 metabolites, 58 metabolites exhibited significant changes (VIP > 1.5, FDR p < 0.05). 5 × 5 nested cross-validation combining an inner-loop LASSO feature selection model yielded a pooled out-of-fold AUC of 0.958 (95% CI (DeLong): 0.940–0.977) for TRS classification. Further correlation analyses revealed distinct associations between the top five predictive metabolites and cognitive domains in TRS versus non-TRS patients. Gamma-glutamylthreonine (gamma-Glu-Thr) showed a significant negative correlation with visuospatial cognition in TRS patients (r = −0.25, p = 0.009). In contrast, it showed a positive correlation in the non-TRS group (r = 0.16, p = 0.015). However, these associations did not remain significant after FDR correction. This study established an RF-metabolomic model for identifying TRS and provided specific metabolic signatures associated with cognitive dysfunction.
- 19 August 2026
- Published by Springer Nature in Molecular Psychiatry
- p. 1-10
Metabolic biomarkers of treatment-resistant schizophrenia and cognitive correlates: insights from a machine learning
Early identification of Treatment-resistant schizophrenia (TRS) remains a challenge. Metabolomics offers a promising strategy for identifying biomarkers and uncovering the metabolic alterations underlying TRS. Machine learning (ML), increasingly applied in omics research, enables the development of predictive models from complex datasets. This study aimed to develop a metabolomics-based ML model for TRS identification and to examine its association with cognitive impairments. 112 TRS patients, 232 non-TRS patients, and 145 sex- and age-matched healthy controls were recruited in this study. Psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS), and cognitive function was evaluated with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the Toronto Alexithymia Scale (TAS-26). Fasting blood samples were collected from all participants and analyzed by UHPLC-HRMS, enabling the quantification and profiling of 699 metabolites. The resulting data were then subjected to orthogonal partial least squares discriminant analysis (OPLS-DA), and a predictive model was constructed using a random forest algorithm, which was validated through 5 × 5 nested cross-validation with inner-loop LASSO feature selection. From 699 metabolites, 58 metabolites exhibited significant changes (VIP > 1.5, FDR p < 0.05). 5 × 5 nested cross-validation combining an inner-loop LASSO feature selection model yielded a pooled out-of-fold AUC of 0.958 (95% CI (DeLong): 0.940–0.977) for TRS classification. Further correlation analyses revealed distinct associations between the top five predictive metabolites and cognitive domains in TRS versus non-TRS patients. Gamma-glutamylthreonine (gamma-Glu-Thr) showed a significant negative correlation with visuospatial cognition in TRS patients (r = −0.25, p = 0.009). In contrast, it showed a positive correlation in the non-TRS group (r = 0.16, p = 0.015). However, these associations did not remain significant after FDR correction. This study established an RF-metabolomic model for identifying TRS and provided specific metabolic signatures associated with cognitive dysfunction.
- 14 August 2026
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 124, 105124
Individualized temporal interference stimulation targeting the right nucleus accumbens in schizophrenia: An open-label pilot study
- 14 August 2026
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 124, 105124
Individualized temporal interference stimulation targeting the right nucleus accumbens in schizophrenia: An open-label pilot study
- Open Access
- 17 September 2025
- Published by Springer Nature in Research Square
Cognitive Impairments and Plasma Metabolic Characteristics in Deficit Schizophrenia: A Two-Year Follow-Up Longitudinal Study
Background: Deficit schizophrenia (DS) is a clinically distinct subtype of schizophrenia (SZ) characterized by enduring primary negative symptoms. However, its long-term cognitive trajectory and metabolic profile remain poorly understood. This study aimed to examine progressive cognitive impairments in DS over a two-year period and to identify associated plasma metabolites and potential diagnostic biomarkers using untargeted metabolomics. Methods: A total of 126 hospitalized patients (51 DS and 75 non-DS) completed cognitive and symptom assessments using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the Positive and Negative Syndrome Scale (PANSS) at baseline and two-year follow-up. Fasting plasma samples collected at baseline were analyzed using untargeted metabolomics. Repeated-measures ANOVA assessed cognitive changes in DS patients. LASSO regression, combined with cross-validation, identified potential diagnostic metabolites and their associations with cognitive impairments. Results: Over two years, patients with DS showed significant declines in cognition, mainly in visuospatial/constructional ability, attention, and delayed memory. Untargeted metabolomics identified 34 differential metabolites, primarily amino acids, fatty acids, and acylcarnitines. Pathway enrichment analysis revealed abnormalities in histidine metabolism, alanine-aspartate-glutamate metabolism, and lysine degradation. Further LASSO regression identified a 20-metabolite panel that accurately distinguished DS from non-DS patients, with an AUC of 0.929 (95% CI: 0.887-0.970). Several metabolites, including aminoadipic acid, succinylcarnitine, and gamma-glutamylthreonine, were significantly associated with cognitive impairments. Conclusions: This study is the first to reveal progressive cognitive impairments and distinct plasma metabolites in DS, identifying potential diagnostic markers and insights into its mechanisms.
- 17 September 2025
- Published by Springer Nature in Research Square
Open AccessCognitive Impairments and Plasma Metabolic Characteristics in Deficit Schizophrenia: A Two-Year Follow-Up Longitudinal Study
Background: Deficit schizophrenia (DS) is a clinically distinct subtype of schizophrenia (SZ) characterized by enduring primary negative symptoms. However, its long-term cognitive trajectory and metabolic profile remain poorly understood. This study aimed to examine progressive cognitive impairments in DS over a two-year period and to identify associated plasma metabolites and potential diagnostic biomarkers using untargeted metabolomics. Methods: A total of 126 hospitalized patients (51 DS and 75 non-DS) completed cognitive and symptom assessments using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the Positive and Negative Syndrome Scale (PANSS) at baseline and two-year follow-up. Fasting plasma samples collected at baseline were analyzed using untargeted metabolomics. Repeated-measures ANOVA assessed cognitive changes in DS patients. LASSO regression, combined with cross-validation, identified potential diagnostic metabolites and their associations with cognitive impairments. Results: Over two years, patients with DS showed significant declines in cognition, mainly in visuospatial/constructional ability, attention, and delayed memory. Untargeted metabolomics identified 34 differential metabolites, primarily amino acids, fatty acids, and acylcarnitines. Pathway enrichment analysis revealed abnormalities in histidine metabolism, alanine-aspartate-glutamate metabolism, and lysine degradation. Further LASSO regression identified a 20-metabolite panel that accurately distinguished DS from non-DS patients, with an AUC of 0.929 (95% CI: 0.887-0.970). Several metabolites, including aminoadipic acid, succinylcarnitine, and gamma-glutamylthreonine, were significantly associated with cognitive impairments. Conclusions: This study is the first to reveal progressive cognitive impairments and distinct plasma metabolites in DS, identifying potential diagnostic markers and insights into its mechanisms.
- 17 October 2024
- Published by Elsevier in Brain Research
- Vol. 1846, 149282
Sex differences in plasma lipid profiles, but not in glucose metabolism in patients with first-episode antipsychotics-naïve schizophrenia
- 17 October 2024
- Published by Elsevier in Brain Research
- Vol. 1846, 149282
Sex differences in plasma lipid profiles, but not in glucose metabolism in patients with first-episode antipsychotics-naïve schizophrenia
- Open Access
- 16 April 2024
- Published by Springer Nature in Schizophrenia
- Vol. 10 (1) , 1-8
Association of cytokines levels, psychopathology and cognition among CR-TRS patients with metabolic syndrome
Clozapine-resistant treatment-refractory schizophrenia (CR-TRS) patients face significant clinical challenges. While links between metabolic syndrome (MetS) and inflammatory cytokines in schizophrenia have been established, the relationship between MetS and cytokine levels in CR-TRS patients remains unexplored. This study aimed to investigate the relationship between cytokines levels, clinical symptoms and cognitive impairments in CR-TRS patients, both with and without MetS. The study included 69 CR-TRS patients (31with MetS and 38 without MetS) and 84 healthy controls. The levels of IL-2, IL-6, TNF-α and routine biochemical parameters were measured. Psychopathological symptoms and cognitive function were assessed using the Positive and Negative Syndrome Scale (PANSS) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), respectively. We found that CR-TRS patients with MetS displayed lower cognitive function scores compared to those without MetS, even when accounting for potential confounders. TNF-α levels were significantly higher in CRTRS patients with MetS compared to those without MetS, demonstrating substantial pathophysiological potential for CR-TRS patients with MetS via receiver operating characteristic curve (ROC). In CR-TRS patients without MetS, IL-2 independently contributed to the total score and general psychopathology subscore of PANSS. Additionally, IL-6 exhibited an independent contribution to the positive subscore of PANSS. In terms of cognition function, IL-6 independently contributed to the delayed memory of RBANS in CR-TRS patients without MetS. TNF-α could potentially serve as a predictive marker for distinguishing between CR-TRS patients with/without MetS, while IL-2 and IL-6 could independently contribute to psychopathological symptoms or cognitive function in CRTRS patients without MetS. Our study provided insights into the potential interplay between cytokines, clinical symptoms and cognitive impairments in CR-TRS patients with/without MetS.
- 16 April 2024
- Published by Springer Nature in Schizophrenia
- Vol. 10 (1) , 1-8
Open AccessAssociation of cytokines levels, psychopathology and cognition among CR-TRS patients with metabolic syndrome
Clozapine-resistant treatment-refractory schizophrenia (CR-TRS) patients face significant clinical challenges. While links between metabolic syndrome (MetS) and inflammatory cytokines in schizophrenia have been established, the relationship between MetS and cytokine levels in CR-TRS patients remains unexplored. This study aimed to investigate the relationship between cytokines levels, clinical symptoms and cognitive impairments in CR-TRS patients, both with and without MetS. The study included 69 CR-TRS patients (31with MetS and 38 without MetS) and 84 healthy controls. The levels of IL-2, IL-6, TNF-α and routine biochemical parameters were measured. Psychopathological symptoms and cognitive function were assessed using the Positive and Negative Syndrome Scale (PANSS) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), respectively. We found that CR-TRS patients with MetS displayed lower cognitive function scores compared to those without MetS, even when accounting for potential confounders. TNF-α levels were significantly higher in CRTRS patients with MetS compared to those without MetS, demonstrating substantial pathophysiological potential for CR-TRS patients with MetS via receiver operating characteristic curve (ROC). In CR-TRS patients without MetS, IL-2 independently contributed to the total score and general psychopathology subscore of PANSS. Additionally, IL-6 exhibited an independent contribution to the positive subscore of PANSS. In terms of cognition function, IL-6 independently contributed to the delayed memory of RBANS in CR-TRS patients without MetS. TNF-α could potentially serve as a predictive marker for distinguishing between CR-TRS patients with/without MetS, while IL-2 and IL-6 could independently contribute to psychopathological symptoms or cognitive function in CRTRS patients without MetS. Our study provided insights into the potential interplay between cytokines, clinical symptoms and cognitive impairments in CR-TRS patients with/without MetS.